Medios stock fell 3.44 percent after the Caelo deal completed

Published on 10/04/2026 at 23:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medios stock now has a 74 percent stake in Caelo after the October 1 closing. H1 2026 revenue rose 8.4 percent to EUR 1,074.9 million, while Q2 net income was EUR 3.54 million.

Makroaufnahme von klaren Glasfläschchen mit Wassertropfen vor blauem Bokeh-Hintergrund — Medios AG (DE000A1MMCC8) steht sinnbildlich für pharmazeutische Präzision, gezeigt in einer Makroaufnahme von Glasfläschchen, Illustration mit AI erstellt.

Medios stock (ISIN DE000A1MMCC8) was last at EUR 10.68 on Xetra on October 2, 2026, down 3.44 percent on the session. The company had completed its acquisition of 74 percent of Caesar & Loretz GmbH, known as Caelo, one day earlier, according to EQS News.

Caelo expands the API platform

The completed transaction makes Medios the market leader in active pharmaceutical ingredients for pharmacies and hospitals in Germany. Options cover the remaining 26 percent of Caelo, while the business is being combined with Magis Pharma in Belgium and Metapharmaceutical in Spain, according to EQS News on October 1, 2026.

Caelo employs 240 people at GMP-certified sites in Hilden and Bonn and expects EUR 40 million of revenue for its current financial year. The deal also creates potential for joint procurement, repacking, cross-selling and broader European distribution.

Revenue grows as margins face pressure

Medios reported H1 2026 revenue of EUR 1,074.9 million, an 8.4 percent year-over-year increase, while its EBITDA pre margin declined to 4.1 percent amid price pressure, higher costs and regulatory effects, according to Quartr.

For the quarter ended June 30, 2026, revenue was EUR 547.31 million versus EUR 507.06 million a year earlier. Net income was EUR 3.54 million, compared with EUR 6.30 million in the prior-year quarter, according to Markets Insider.

2031 targets shape the valuation debate

Medios targets EUR 3.1 billion of group revenue and EUR 170 million of adjusted EBITDA by 2031. The plan builds on two operating segments, with Compounding positioned as the main growth and margin driver, while Specialty Pharma Supply is intended to provide cash generation.

Adjusted EBITDA stood at EUR 87 million in 2025 under the new definition, creating a quantified baseline for the 2031 target. Net debt to EBITDA was 1.32x in H1 2026, according to Markets Insider.

Analyst targets remain above the stock

The Globe and Mail reported a Strong Buy consensus for Medios with an average price target of USD 23.05 on October 2, 2026. Markets Insider also reported that Berenberg maintained a Buy rating with a EUR 22.00 target, while Deutsche Bank maintained Buy with a EUR 16.00 target.

Medios stock falls after the deal

Medios stock was last at EUR 10.68 on Xetra on October 2, 2026, with a daily change of minus 3.44 percent. The market price therefore remained below the EUR 16.00 and EUR 22.00 targets cited in the analyst coverage, leaving the Caelo integration and margin development as the next measurable tests for the strategy.